Polycystic Liver Disease in Kidney Transplant

NCT00934791

Last updated date
Study Location
Mayo Clinic
Rochester, Minnesota, 55905, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Polycystic Liver Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adults (> 18 years old) with stage IV or V chronic kidney due to ADPKD

- Primary kidney transplant

- Living or deceased donor kidney transplant

- Estimate total liver volume of 2.5 to 7.5 L

- In addition, at the discretion of the principal investigator(s), certain subjects with numerous liver cysts but with liver volume < 2.5 liters may be enrolled.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pediatric patients (< 18 years of age)


- Patients with Body Mass Index (BMI) greater than or equal to 40 kg/m^2


- Multi-organ transplant (kidney-liver, etc.)


- When people who have one blood type receive blood from someone with a different blood
type, it may cause their immune system to react. This is called (ABO) incompatibility.
ABO-incompatible or positive cross-match recipients


- Patients with severe hyperlipidemia (serum cholesterol > 350 mg/dl or serum
triglycerides > 500 mg/dl)


- Patients with leukopenia (WBC < 3000 10/ml)


- Patients unwilling to return to the transplant center for late follow-up visits


- Patients who are currently pregnant or breast-feeding or who expect to be pregnant
during the study period


- Female patients of child bearing potential and men with sexual partners of child
bearing potential who do not agree to use a medically accepted method of contraception
during the study period


- Patients who are not eligible for Thymoglobulin induction

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Polycystic Liver DiseasePolycystic Liver Disease in Kidney Transplant
NCT00934791
  1. Rochester, Minnesota
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Polycystic Liver Disease in Kidney Transplant
Official Title  ICMJE Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease
Brief Summary The purpose of this study is to see if one kind of immunosuppressive drug has better effects for the patient's polycystic liver disease than another type. Tacrolimus and Sirolimus are the two immunosuppressive drugs that will be compared for this study. Both drugs have been commonly prescribed to prevent rejection.
Detailed Description

Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening monogenic disease with a prevalence of 1 in 400-1000 livebirths. ADPKD is caused by mutations to polycystic kidney disease 1 gene (PKD1) (approximately 85% of cases) or polycystic kidney disease 2 gene (PKD2) (the remaining 15%) gene, encoding polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 is a putative cell-surface, receptor-like protein with yet to-be-identified ligand(s), and PC2 a channel protein with a high conductance to Ca2+.

Polycystic liver disease (PLD) is the most common extra-renal manifestation in ADPKD, present in > 90% of ADPKD patients by age 30. Liver cysts in ADPKD originate from biliary micro-hamartoma or focal proliferations of biliary ductules and from peribiliary glands. Excessive proliferation of biliary epithelial cells, combined with neovascularization, altered cell-extracellular matrix (ECM) interaction/ECM remodeling and cAMP-mediated fluid secretion, is required for the development and expansion of PLD liver cysts.

PLD may become symptomatic with acute complications such as cyst hemorrhage, rupture and infection. Chronic symptoms are frequently associated with massively enlarged PLD, including abdominal distension and pain; dyspnea; gastroesophageal reflux and early satiety which may lead to malnutrition; mechanical lower back pain; obstruction of the inferior vena cava, hepatic and portal veins (leading to dialysis-associated hypotension, hepatic venous outflow obstruction, and portal hypertension) and biliary obstruction. Currently, apart from invasive interventions such as cyst aspiration with sclerosis, cyst fenestration combined hepatic resection and cyst fenestration, liver transplantation and, rarely, selective hepatic artery embolization, no medical therapy is available.

The objective of this study is to conduct a prospective, open-label, randomized trial to examine the effect of sirolimus on total liver volume in kidney transplant recipients with ADPKD.

Four weeks following kidney transplant, subjects will undergo iothalamate clearance measurement, 24-hour urine collection and protein measurement and physical examination by a transplant surgeon. Patients will be randomized to receive either sirolimus-based immunosuppression or to continue tacrolimus-based immunosuppression unless one of the following conditions are noted:

  1. Complications of the kidney transplant incision, including, but not limited to: superficial wound infection, deep wound infection, and fascial dehiscence
  2. Iothalamate clearance measurement less than 40 mL/min/1.72m^2
  3. Urinary protein excretion greater than 800 mg/24 hours. Subjects with the above conditions will continue to receive tacrolimus-based immunosuppression at the discretion of the treating physician/surgeon.

Enrolled subjects will undergo abdominal and pelvic CT scans within 3 months before or after kidney transplantation and at one, two, and three years after kidney transplantation.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Polycystic Liver Disease
Intervention  ICMJE
  • Drug: Tacrolimus
    Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
    Other Name: Prograf
  • Drug: Sirolimus
    Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
    Other Names:
    • Rapamune
    • Rapamycin
  • Drug: Mycophenolate Mofetil
    Mycophenolate Mofetil 750 mg twice daily
    Other Name: Cellcept
  • Drug: Prednisone
    Prednisone tapered to 5 mg/day by day 92
    Other Name: Deltasone
Study Arms  ICMJE
  • Active Comparator: Control Group
    Tacrolimus, mycophenolate mofetil, and prednisone
    Interventions:
    • Drug: Tacrolimus
    • Drug: Mycophenolate Mofetil
    • Drug: Prednisone
  • Active Comparator: Sirolimus Group
    Sirolimus, mycophenolate mofetil, and prednisone
    Interventions:
    • Drug: Sirolimus
    • Drug: Mycophenolate Mofetil
    • Drug: Prednisone
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: January 9, 2013)
2
Original Estimated Enrollment  ICMJE
 (submitted: July 7, 2009)
68
Actual Study Completion Date  ICMJE December 2012
Actual Primary Completion Date December 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adults (> 18 years old) with stage IV or V chronic kidney due to ADPKD
  • Primary kidney transplant
  • Living or deceased donor kidney transplant
  • Estimate total liver volume of 2.5 to 7.5 L
  • In addition, at the discretion of the principal investigator(s), certain subjects with numerous liver cysts but with liver volume < 2.5 liters may be enrolled.

Exclusion Criteria:

  • Pediatric patients (< 18 years of age)
  • Patients with Body Mass Index (BMI) greater than or equal to 40 kg/m^2
  • Multi-organ transplant (kidney-liver, etc.)
  • When people who have one blood type receive blood from someone with a different blood type, it may cause their immune system to react. This is called (ABO) incompatibility. ABO-incompatible or positive cross-match recipients
  • Patients with severe hyperlipidemia (serum cholesterol > 350 mg/dl or serum triglycerides > 500 mg/dl)
  • Patients with leukopenia (WBC < 3000 10/ml)
  • Patients unwilling to return to the transplant center for late follow-up visits
  • Patients who are currently pregnant or breast-feeding or who expect to be pregnant during the study period
  • Female patients of child bearing potential and men with sexual partners of child bearing potential who do not agree to use a medically accepted method of contraception during the study period
  • Patients who are not eligible for Thymoglobulin induction
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00934791
Other Study ID Numbers  ICMJE 08-004315
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Patrick G. Dean, Mayo Clinic
Study Sponsor  ICMJE Mayo Clinic
Collaborators  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Investigators  ICMJE
Principal Investigator:Patrick Dean, M.D.Mayo Clinic
Principal Investigator:QI Qian, MDMayo Clinic
PRS Account Mayo Clinic
Verification Date February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP